[1]
A. Aiello, M. E. Mancuso, S. Leone, L. Rossi, L. Cioni, and C. Teruzzi, “Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update”, Grhta, vol. 9, no. 1, pp. 9–13, Jan. 2022.